Metabolic network-based identification and prioritization of anticancer targets based on expression data in hepatocellular carcinoma

Frontiers in Physiology

Volumn 9, Issue JUL, 2018, Pages

  Bidkhori, Gholamreza ^a   Benfeitas, Rui ^a   Elmas, Ezgi ^a   Kararoudi, Meisam Naeimi ^a   Arif, Muhammad ^a   Uhlen, Mathias ^a   Nielsen, Jens ^b   Mardinoglu, Adil ^a,b  

^a ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^b CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

Author keywords

Biological networks; Cancer; Gene expression; Genome scale metabolic model; Hepatocellular carcinoma; Network analysis; Protein expression; Systems biology and network biology

Indexed keywords

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL GROWTH; CLINICAL ARTICLE; CRLS1 GENE; DRUG APPROVAL; DRUG IDENTIFICATION; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; GENE TARGETING; GENETIC ALGORITHM; HEP 3B2.1-7 CELL LINE; HEP-G2 CELL LINE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PGS1 GENE; PRKACA GENE; TRANSCRIPTOMICS; TUMOR GENE;

EID: 85050120958     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2018.00916     Document Type: Article

References (48)

1. Agren, R., Liu, L., Shoaie, S., Vongsangnak, W., Nookaew, I., and Nielsen, J. (2013). The RAVEN toolbox and its use for generating a genome-scale metabolic model for Penicillium chrysogenum. PLoS Comput. Biol. 9:e1002980. doi: 10.1371/journal.pcbi.1002980
2. Agren, R., Mardinoglu, A., Asplund, A., Kampf, C., Uhlen, M., and Nielsen, J. (2014). Identification of anticancer drugs for hepatocellular carcinoma through personalized genome-scale metabolic modeling. Mol. Syst. Biol. 10:721. doi: 10.1002/msb.145122
3. Altekruse, S. F., Mcglynn, K. A., and Reichman, M. E. (2009). Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J. Clin. Oncol. 27, 1485-1491. doi: 10.1200/JCO.2008.20.7753
4. Asgari, Y., Salehzadeh-Yazdi, A., Schreiber, F., and Masoudi-Nejad, A. (2013). Controllability in cancer metabolic networks according to drug targets as driver nodes. PLoS ONE 8:e79397. doi: 10.1371/journal.pone.0079397
5. Barabasi, A. L., Gulbahce, N., and Loscalzo, J. (2011). Network medicine: a network-based approach to human disease. Nat. Rev. Genet. 12, 56-68. doi: 10.1038/nrg2918
6. Benfeitas, R., Uhlen, M., Nielsen, J., and Mardinoglu, A. (2017). New challenges to study heterogeneity in cancer redox metabolism. Front. Cell Dev. Biol. 5:65. doi: 10.3389/fcell.2017.00065
7. Bhutia, Y. D., Babu, E., Ramachandran, S., and Ganapathy, V. (2015). Amino Acid transporters in cancer and their relevance to 'glutamine addiction': novel targets for the design of a new class of anticancer drugs. Cancer Res. 75, 1782-1788. doi: 10.1158/0008-5472.CAN-14-3745
8. Ferlay, J., Shin, H. R., Bray, F., Forman, D., Mathers, C., and Parkin, D. M. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893-2917 doi: 10.1002/ijc.25516
9. Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., et al. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359-386. doi: 10.1002/ijc.29210
10. Folger, O., Jerby, L., Frezza, C., Gottlieb, E., Ruppin, E., and Shlomi, T. (2011). Predicting selective drug targets in cancer through metabolic networks. Mol. Syst. Biol. 7:501. doi: 10.1038/msb.2011.35
11. Friemel, J., Rechsteiner, M., Frick, L., Bohm, F., Struckmann, K., Egger, M., et al. (2015). Intratumor heterogeneity in hepatocellular carcinoma. Clin. Cancer Res. 21, 1951-1961 doi: 10.1158/1078-0432.CCR-14-0122
12. Fung, M. K. L., and Chan, G. C. (2017). Drug-induced amino acid deprivation as strategy for cancer therapy. J. Hematol. Oncol. 10:144. doi: 10.1186/s13045-017-0509-9
13. Gao, Y., Lin, L. P., Zhu, C. H., Chen, Y., Hou, Y. T., and Ding, J. (2006). Growth arrest induced by C75, A fatty acid synthase inhibitor, was partially modulated by p38 MAPK but not by p53 in human hepatocellular carcinoma. Cancer Biol. Ther. 5, 978-985. doi: 10.4161/cbt.5.8.2883
14. Grossman, R. L., Heath, A. P., Ferretti, V., Varmus, H. E., Lowy, D. R., Kibbe, W. A., et al. (2016). Toward a shared vision for cancer genomic data. N. Engl. J. Med. 375, 1109-1112. doi: 10.1056/NEJMp1607591
15. Guney, E., Menche, J., Vidal, M., and Barabasi, A. L. (2016). Network-based in silico drug efficacy screening. Nat. Commun. 7:10331. doi: 10.1038/ncomms10331
16. Hartung, F., Wang, Y., Aronow, B., and Weber, G. F. (2017). A core program of gene expression characterizes cancer metastases. Oncotarget 8, 102161-102175. doi: 10.18632/oncotarget.22240
17. Hirsch, H. A., Iliopoulos, D., Joshi, A., Zhang, Y., Jaeger, S. A., Bulyk, M., et al. (2010). A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases. Cancer Cell 17, 348-361. doi: 10.1016/j.ccr.2010.01.022
18. Honeyman, J. N., Simon, E. P., Robine, N., Chiaroni-Clarke, R., Darcy, D. G., Lim, I. I., et al. (2014). Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science 343, 1010-1014. doi: 10.1126/science.1249484
19. Jeong, H., Mason, S. P., Barabasi, A. L., and Oltvai, Z. N. (2001). Lethality and centrality in protein networks. Nature 411, 41-42. doi: 10.1038/35075138
20. Jonsson, P. F., and Bates, P. A. (2006). Global topological features of cancer proteins in the human interactome. Bioinformatics 22, 2291-2297. doi: 10.1093/bioinformatics/btl390
21. Kanhaiya, K., Czeizler, E., Gratie, C., and Petre, I. (2017). Controlling directed protein interaction networks in cancer. Sci. Rep. 7:10327. doi: 10.1038/s41598-017-10491-y
22. Khosraviani, M., Saheb Zamani, M., and Bidkhori, G. (2016). FogLight: an efficient matrix-based approach to construct metabolic pathways by search space reduction. Bioinformatics 32, 398-408. doi: 10.1093/bioinformatics/btv578
23. Kuhajda, F. P., Pizer, E. S., Li, J. N., Mani, N. S., Frehywot, G. L., and Townsend, C. A. (2000). Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc. Natl. Acad. Sci. U.S.A. 97, 3450-3454. doi: 10.1073/pnas.97.7.3450
24. Law, V., Knox, C., Djoumbou, Y., Jewison, T., Guo, A. C., Liu, Y., et al. (2014). DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 42, D1091-D1097. doi: 10.1093/nar/gkt1068
25. Liu, Y. Y., Slotine, J. J., and Barabasi, A. L. (2011). Controllability of complex networks. Nature 473, 167-173. doi: 10.1038/nature10011
26. Lv, W., Xu, Y., Guo, Y., Yu, Z., Feng, G., Liu, P., et al. (2016). The drug target genes show higher evolutionary conservation than non-target genes. Oncotarget 7, 4961-4971. doi: 10.18632/oncotarget.6755
27. Maddocks, O. D. K., Athineos, D., Cheung, E. C., Lee, P., Zhang, T., Van Den Broek, N. J. F., et al. (2017). Modulating the therapeutic response of tumours to dietary serine and glycine starvation. Nature 544, 372-376. doi: 10.1038/nature22056
28. Mardinoglu, A., Agren, R., Kampf, C., Asplund, A., Uhlen, M., and Nielsen, J. (2014a). Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease. Nat. Commun. 5:3083. doi: 10.1038/ncomms4083
29. Mardinoglu, A., Gatto, F., and Nielsen, J. (2013). Genome-scale modeling of human metabolism-a systems biology approach. Biotechnol. J. 8, 985-996. doi: 10.1002/biot.201200275
30. Mardinoglu, A., and Nielsen, J. (2012). Systems medicine and metabolic modelling. J. Intern. Med. 271, 142-154. doi: 10.1111/j.1365-2796.2011.02493.x
31. Mardinoglu, A., and Nielsen, J. (2015). New paradigms for metabolic modeling of human cells. Curr. Opin. Biotechnol. 34, 91-97. doi: 10.1016/j.copbio.2014.12.013
32. Mardinoglu, A., Uhlen, M., and Nielsen, J. (2014b). The use of Genome-scale metabolic models for drug target and biomarker identification. N. Biotechnol. 31, S49-S49. doi: 10.1158/1078-0432.CCR-12-1856
33. Moody, S. E., Schinzel, A. C., Singh, S., Izzo, F., Strickland, M. R., Luo, L., et al. (2015). PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling. Oncogene 34, 2061-2071. doi: 10.1038/onc.2014.153
34. Najafi, A., Bidkhori, G., Bozorgmehr, J. H., Koch, I., and Masoudi-Nejad, A. (2014). Genome scale modeling in systems biology: algorithms and resources. Curr. Genomics 15, 130-159. doi: 10.2174/1389202915666140319002221
35. Qiu, G. H., Xie, X., Xu, F., Shi, X., Wang, Y., and Deng, L. (2015). Distinctive pharmacological differences between liver cancer cell lines HepG2 and Hep3B. Cytotechnology 67, 1-12. doi: 10.1007/s10616-014-9761-9
36. Sabbisetti, V. S., Chirugupati, S., Thomas, S., Vaidya, K. S., Reardon, D., Chiriva-Internati, M., et al. (2005). Calcitonin increases invasiveness of prostate cancer cells: role for cyclic AMP-dependent protein kinase A in calcitonin action. Int. J. Cancer 117, 551-560. doi: 10.1002/ijc.21158
37. Sapandowski, A., Stope, M., Evert, K., Evert, M., Zimmermann, U., Peter, D., et al. (2015). Cardiolipin composition correlates with prostate cancer cell proliferation. Mol. Cell. Biochem. 410, 175-185. doi: 10.1007/s11010-015-2549-1
38. Schug, Z. T., and Gottlieb, E. (2009). Cardiolipin acts as a mitochondrial signalling platform to launch apoptosis. Biochim. Biophys. Acta 1788, 2022-2031. doi: 10.1016/j.bbamem.2009.05.004
39. Sontag, E. D. (2013). Mathematical Control Theory: Deterministic Finite Dimensional Systems. New York, NY: Springer Science & Business Media
40. Uhlen, M., Zhang, C., Lee, S., Sjostedt, E., Fagerberg, L., Bidkhori, G., et al. (2017). A pathology atlas of the human cancer transcriptome. Science 357:eaan2507. doi: 10.1126/science.aan2507
41. Varemo, L., Scheele, C., Broholm, C., Mardinoglu, A., Kampf, C., Asplund, A., et al. (2015). Proteome-and transcriptome-driven reconstruction of the human myocyte metabolic network and its use for identification of markers for diabetes. Cell Rep. 11, 921-933. doi: 10.1016/j.celrep.2015.04.010
42. Vinayagam, A., Gibson, T. E., Lee, H. J., Yilmazel, B., Roesel, C., Hu, Y., et al. (2016). Controllability analysis of the directed human protein interaction network identifies disease genes and drug targets. Proc. Natl. Acad. Sci. U.S.A. 113, 4976-4981. doi: 10.1073/pnas.1603992113
43. Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., et al. (2013). The Cancer genome atlas pan-cancer analysis project. Nat. Genet. 45, 1113-1120. doi: 10.1038/ng.2764
44. Wuchty, S. (2014). Controllability in protein interaction networks. Proc. Natl. Acad. Sci. U.S.A. 111, 7156-7160. doi: 10.1073/pnas.1311231111
45. Xiao, F., Wang, C., Yin, H., Yu, J., Chen, S., Fang, J., et al. (2016). Leucine deprivation inhibits proliferation and induces apoptosis of human breast cancer cells via fatty acid synthase. Oncotarget 7, 63679-63689. doi: 10.18632/oncotarget.11626
46. Xie, X. L., Wei, M., Yunoki, T., Kakehashi, A., Yamano, S., Kato, M., et al. (2012). Long-term treatment with L-isoleucine or L-leucine in AIN-93G diet has promoting effects on rat bladder carcinogenesis. Food Chem. Toxicol. 50, 3934-3940. doi: 10.1016/j.fct.2012.07.063
47. Yu, H., Braun, P., Yildirim, M. A., Lemmens, I., Venkatesan, K., Sahalie, J., et al. (2008). High-quality binary protein interaction map of the yeast interactome network. Science 322, 104-110. doi: 10.1126/science.1158684
48. Yuan, Z., Zhao, C., Di, Z., Wang, W. X., and Lai, Y. C. (2013). Exact controllability of complex networks. Nat. Commun. 4:2447. doi: 10.1038/ncomms3447